Isavuconazonium sulfate is an orally bioavailable, safe, second-generation triazole antifungal agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of invasive Aspergillosis and invasive Mucormycosis in adults 18 years of age and older. Currently available under the brand name Cresemba, the most common side effects include liver test abnormalities, nausea, vomiting, dyspnea, abdominal pain, diarrhoea, injection site reactions, headache, hypokalemia and rash.
Isavuconazonium Sulfate can be prepared to be used as an antifungal drug.
ChEBI: An azaheterocycle sulfate salt that is a prodrug for isavuconazole, an antifungal agent used for the treatment of invasive aspergillosis and invasive mucormycosis.
Isavuconazonium sulfate (Cresemba) is the water-soluble prodrug of isavuconazole, a broad-spectrum antifungal triazoles with activity against yeasts, molds, and dimorphic fungi and available as intravenous solution and as capsules for oral administration. Isavuconazonium sulfate is metabolized mainly by serum butylcholinesterase to isavuconazole. Isavuconazole is metabolized to inactive metabolites in the liver via CYP3A4 and CYP3A5 isoenzymes and uridine diphosphate-glucuronosyl transferase[1].
[1] Kumar, Sunil et al. “11. Thiazole: A privileged scaffold in drug discovery.” 2016. 0.
